FR2915683B1 - Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif - Google Patents

Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif

Info

Publication number
FR2915683B1
FR2915683B1 FR0703186A FR0703186A FR2915683B1 FR 2915683 B1 FR2915683 B1 FR 2915683B1 FR 0703186 A FR0703186 A FR 0703186A FR 0703186 A FR0703186 A FR 0703186A FR 2915683 B1 FR2915683 B1 FR 2915683B1
Authority
FR
France
Prior art keywords
precipitant
self
active ingredients
pharmaceutical formulations
modified release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0703186A
Other languages
English (en)
Other versions
FR2915683A1 (fr
Inventor
Frederic Checot
Gonnet Cecile Bonnet
You Ping Chan
Olivier Breyne
Remi Meyrueix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flamel Technologies SA
Original Assignee
Flamel Technologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0703186A priority Critical patent/FR2915683B1/fr
Application filed by Flamel Technologies SA filed Critical Flamel Technologies SA
Priority to MX2009011814A priority patent/MX2009011814A/es
Priority to AU2008248603A priority patent/AU2008248603A1/en
Priority to US12/149,541 priority patent/US8236353B2/en
Priority to CN200880014417A priority patent/CN101674809A/zh
Priority to JP2010504756A priority patent/JP2010526041A/ja
Priority to EP08750063A priority patent/EP2155164A1/fr
Priority to CA002685873A priority patent/CA2685873A1/fr
Priority to KR1020097023698A priority patent/KR20100016513A/ko
Priority to BRPI0809288-5A2A priority patent/BRPI0809288A2/pt
Priority to PCT/EP2008/055506 priority patent/WO2008135562A1/fr
Publication of FR2915683A1 publication Critical patent/FR2915683A1/fr
Application granted granted Critical
Publication of FR2915683B1 publication Critical patent/FR2915683B1/fr
Priority to IL201465A priority patent/IL201465A0/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0703186A 2007-05-03 2007-05-03 Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif Expired - Fee Related FR2915683B1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR0703186A FR2915683B1 (fr) 2007-05-03 2007-05-03 Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
KR1020097023698A KR20100016513A (ko) 2007-05-03 2008-05-05 활성 성분의 조절 방출을 위한 자가 침전 약학 제제
US12/149,541 US8236353B2 (en) 2007-05-03 2008-05-05 Self-precipitating pharmaceutical formulations for the modified release of an active principle
CN200880014417A CN101674809A (zh) 2007-05-03 2008-05-05 用于改进释放活性成分的自沉淀药物制剂
JP2010504756A JP2010526041A (ja) 2007-05-03 2008-05-05 活性成分を制御放出するための自己沈澱製剤
EP08750063A EP2155164A1 (fr) 2007-05-03 2008-05-05 Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
MX2009011814A MX2009011814A (es) 2007-05-03 2008-05-05 Formulaciones farmaceuticas autoprecipitantes para la liberacion modificada de un principio activo.
AU2008248603A AU2008248603A1 (en) 2007-05-03 2008-05-05 Self-precipitating pharmaceutical formulations for the modified release of active principle
BRPI0809288-5A2A BRPI0809288A2 (pt) 2007-05-03 2008-05-05 Formulações farmacêuticas auto-precipitação para a liberação modificada de um princípio ativo
PCT/EP2008/055506 WO2008135562A1 (fr) 2007-05-03 2008-05-05 Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
CA002685873A CA2685873A1 (fr) 2007-05-03 2008-05-05 Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
IL201465A IL201465A0 (en) 2007-05-03 2009-10-12 Self-precipitating pharmaceutical formulations for the modified release of active principle

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0703186A FR2915683B1 (fr) 2007-05-03 2007-05-03 Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif

Publications (2)

Publication Number Publication Date
FR2915683A1 FR2915683A1 (fr) 2008-11-07
FR2915683B1 true FR2915683B1 (fr) 2009-08-07

Family

ID=39027559

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0703186A Expired - Fee Related FR2915683B1 (fr) 2007-05-03 2007-05-03 Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif

Country Status (12)

Country Link
US (1) US8236353B2 (fr)
EP (1) EP2155164A1 (fr)
JP (1) JP2010526041A (fr)
KR (1) KR20100016513A (fr)
CN (1) CN101674809A (fr)
AU (1) AU2008248603A1 (fr)
BR (1) BRPI0809288A2 (fr)
CA (1) CA2685873A1 (fr)
FR (1) FR2915683B1 (fr)
IL (1) IL201465A0 (fr)
MX (1) MX2009011814A (fr)
WO (1) WO2008135562A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012159945A1 (fr) * 2011-05-20 2012-11-29 Ares Trading S.A. Composition à base d'ifn bêta, procédés de préparation et utilisations associés
KR101810055B1 (ko) 2011-08-10 2017-12-18 아도시아 하나 이상의 유형의 기저 인슐린의 주사액
US9198971B2 (en) * 2012-01-09 2015-12-01 Adocia Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
WO2017211917A1 (fr) * 2016-06-07 2017-12-14 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide statistique
FR3052072A1 (fr) * 2016-06-07 2017-12-08 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CN111698999A (zh) * 2017-12-06 2020-09-22 阿道恰公司 包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph为7的可注射溶液

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239408T3 (es) 1997-10-03 2005-09-16 Macromed Inc. Copolimeros tribloque de poli(lactido-co-glicolido) polietilenglicol de bajo peso molecular biodegradables con propiedades de gelificacion termica inversa.
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
EP0963758A3 (fr) * 1998-05-07 2000-03-22 Universiteit Gent Synthetique polyaminoacide complexes pour l'apport des acides nucleiques aux celles cibles
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
FR2786098B1 (fr) 1998-11-20 2003-05-30 Flamel Tech Sa Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
FR2801226B1 (fr) 1999-11-23 2002-01-25 Flamel Tech Sa Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
FR2862536B1 (fr) 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
FR2881140B1 (fr) * 2005-01-27 2007-04-06 Flamel Technologies Sa Copolyhydroxyalkylglutamines fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2892725B1 (fr) 2005-10-31 2011-03-04 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des derives de l'histidine et des groupements hydrophobes et leurs applications notamment therapeutiques
FR2915748B1 (fr) 2007-05-03 2012-10-19 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des groupes cationiques et des groupements hydrophobes et leurs applications, notamment therapeutiques

Also Published As

Publication number Publication date
BRPI0809288A2 (pt) 2014-10-14
FR2915683A1 (fr) 2008-11-07
JP2010526041A (ja) 2010-07-29
IL201465A0 (en) 2010-05-31
KR20100016513A (ko) 2010-02-12
EP2155164A1 (fr) 2010-02-24
US8236353B2 (en) 2012-08-07
CN101674809A (zh) 2010-03-17
AU2008248603A1 (en) 2008-11-13
WO2008135562A1 (fr) 2008-11-13
MX2009011814A (es) 2009-11-13
US20090011028A1 (en) 2009-01-08
CA2685873A1 (fr) 2008-11-13

Similar Documents

Publication Publication Date Title
FR2915683B1 (fr) Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif
HRP20191005T1 (hr) Postupak sušenja bibw2992, njegovih soli i čvrstih farmaceutskih formulacija koje sadrže taj djelatni sastojak
FR2902007B1 (fr) Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques
BRPI0817075A2 (pt) núcleos de fármaco para liberação prolongada de agentes terapêuticos
DK2058317T3 (da) Aminophosphorsyreesterderivat og S1P receptormodulator indeholdende samme som aktiv ingrediens
BRPI0821732A2 (pt) Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
IL192773A0 (en) Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol
BRPI0815613A2 (pt) Composições lipossômicas para administração in vivo de compostos de ácido borônico.
EP2174667A4 (fr) Agent pour le traitement de l'ophtalmie contenant un inhibiteur du récepteur de l'interleukine 6 en tant qu'ingrédient actif
BRPI0810439A2 (pt) Formulações farmacêuticas contendo derivados de ácido lipóico
IL208370A0 (en) Improved formulations for poorly permeable active pharmaceutical ingredients
BRPI0913235A2 (pt) forma de dosagem farmacêutica para liberação imediata de um derivado de indolinona
BRPI0912428A2 (pt) formulação farmacêutica sólida de liberação retardada
BRPI0814043A2 (pt) composição farmacêutica para aplicação tópica de compostos pouco solúveis
BRPI0810025A2 (pt) Formulação farmacêutica oral de liberação imediata, método para preparar uma formulação farmacêutica multiparticulada, e, uso de ácido ursodesoxicólico
BRPI0818702A2 (pt) Formulação farmacêutica de ácido clavulânico
BRPI0918539A2 (pt) preparação farmacêutica sólida para administração oral
BRPI0912890A2 (pt) composição farmacêutica para o tratamento de ejaculação precoce
BRPI0812250A2 (pt) Composição farmacêutica de liberação lenta feita de micropartículas
FR2915684B1 (fr) Particules a base de polyelectrolytes et de principe actif a liberation modifiee et formulations pharmaceutiques contenant ces particules
NO20100114L (no) Smakstilsatt leirebasert farmasoytisk preparat
BRPI0821985A2 (pt) Preparacao farmacêutica ou nutracêutica revestida tendo liberação de substância ativa controlada
BRPI0923379A2 (pt) Formulação para administração por via transmucosa oral de setronas
HK1122731A1 (en) Prolonged release formulation of active pharmaceutical ingredients
FR2926722B1 (fr) Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20150130